[{"data":1,"prerenderedAt":168},["ShallowReactive",2],{"drug-pazopanib":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":35,"contraindications":66,"warnings":67,"renal":82,"monitoring":83,"interactions":84,"review":85,"examples":88,"atc":95,"iran":97,"usApproval":104,"links":110,"populations":124},"pazopanib",1,{"fa":7,"en":8},"پازوپانیب","Pazopanib","antineoplastic-immunomodulating",{"fa":11,"en":12},"مهارکننده چندکینازی","Multikinase inhibitor",[14],{"name":15,"market":16},"Votrient","US",[18,19,7],"votrient","ووترینت",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-200","tablet","oral","200 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},200,"mg",false,[16],[32],{"source":33,"section":34},"fda-votrient","3",[36],{"id":37,"disease":38,"label":39,"population":42,"type":46,"unit":28,"dose":47,"refs":49,"notes":52},"rcc","renal-cell-carcinoma",{"fa":40,"en":41},"RCC پیشرفته و سارکوم بافت نرم پیشرفته — ۸۰۰ mg یک بار در روز بدون غذا","Advanced RCC and advanced soft-tissue sarcoma — 800 mg once daily without food",{"minAge":43},{"value":44,"unit":45},18,"year","fixed",{"perDose":48,"dosesPerDay":5},800,[50],{"source":33,"section":51},"2.1",[53,59],{"text":54,"refs":57},{"fa":55,"en":56},"فقط زیر نظر متخصص انکولوژی؛ ادامه تا پیشرفت بیماری یا سمیت غیرقابل‌قبول. تنظیم دوز برای عوارض و تداخل‌ها طبق برچسب.","Only under an oncologist; continue until progression or unacceptable toxicity. Dose adjustments for toxicity and interactions per label.",[58],{"source":33,"section":51},{"text":60,"refs":63},{"fa":61,"en":62},"نارسایی متوسط کبد: ۲۰۰ mg یک بار در روز.","Moderate hepatic impairment: 200 mg once daily.",[64],{"source":33,"section":65},"2.2",[],[68,75],{"text":69,"refs":72},{"fa":70,"en":71},"هشدار جعبه‌ای: سمیت کبدی شدید و کشنده — پایش عملکرد کبد.","Boxed warning: severe and fatal hepatotoxicity — monitor liver function.",[73],{"source":33,"section":74},"Boxed Warning",{"text":76,"refs":79},{"fa":77,"en":78},"QT طولانی؛ اختلال عملکرد قلب؛ خونریزی؛ ترومبوز شریانی و وریدی؛ TMA؛ سوراخ شدن گوارش؛ پنومونیت؛ PRES؛ فشار خون.","QT prolongation; cardiac dysfunction; haemorrhage; arterial and venous thrombosis; TMA; GI perforation; pneumonitis; PRES; hypertension.",[80],{"source":33,"section":81},"5",[],[],[],{"status":86,"reviewer":87,"date":87},"unverified",null,[89],{"regimen":37,"formulation":22,"input":90,"expect":93},{"ageYears":91,"weightKg":92},55,70,{"perDose":48,"tabletsPerDoseRounded":94},4,[96],"L01EX03",{"status":98,"refs":99},"not-found",[100],{"source":101,"section":102,"url":103},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Pazopanib",{"kind":105,"refs":106,"id":109},"NDA",[107],{"source":33,"section":108},"SPL approval \u002F marketing category","NDA022465",[111,114,118,121],{"kind":112,"url":113,"label":109},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=022465",{"kind":115,"url":116,"label":117},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=eeaaaf38-fb86-4d9f-a19d-0f61daac2fd7","FDA Votrient",{"kind":119,"url":120,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa610013.html",{"kind":122,"url":123,"label":96},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=L01EX03",{"pregnancy":125,"lactation":134,"pediatric":142,"geriatric":151,"reproductive":160},{"level":126,"text":127,"quote":130,"refs":131},"avoid",{"fa":128,"en":129},"برچسب: می‌تواند به جنین آسیب بزند. در بارداری خطرناک است.","Label: can cause fetal harm. Dangerous in pregnancy.","Risk Summary Based on animal reproduction studies and its mechanism of action [see Clinical Pharmacology (12.1)] , VOTRIENT can cause fetal harm when administered to a pregnant woman.",[132],{"source":33,"section":133},"8.1",{"level":126,"text":135,"quote":138,"refs":139},{"fa":136,"en":137},"برچسب: شیردهی توصیه نمی‌شود یا باید بین دارو و شیردهی یکی انتخاب شود.","Label: breastfeeding not recommended, or choose between the drug and breastfeeding.","Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with VOTRIENT and for 2 weeks after the final dose.",[140],{"source":33,"section":141},"8.2",{"level":143,"text":144,"quote":147,"refs":148},"not-established",{"fa":145,"en":146},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","The safety and effectiveness of VOTRIENT in pediatric patients have not been established.",[149],{"source":33,"section":150},"8.4",{"level":152,"text":153,"quote":156,"refs":157},"caution",{"fa":154,"en":155},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","More patients ≥ 65 years had ALT elevations > 3 × ULN compared to patients \u003C 65 years (23% versus 18%) [see Warnings and Precautions (5.1)] .",[158],{"source":33,"section":159},"8.5",{"level":152,"text":161,"quote":164,"refs":165},{"fa":162,"en":163},"برچسب نکته‌ای درباره بارداری، پیشگیری یا باروری زنان و مردان دارد.","Label has advice on pregnancy testing, contraception or fertility for females and males.","Contraception Females Advise females of reproductive potential to use effective contraception during treatment with VOTRIENT and for at least 2 weeks after the last dose.",[166],{"source":33,"section":167},"8.3",1792444416242]